Join our daily newsletter At The Bell to receive exclusive market insights
Memphasys Ltd (ASX:MEM) has seen a boost to its proprietary antioxidant profiling system RoXsta through the publication of a recent manuscript that emphasises its commercial potential and scientific credibility.
The publication, ‘A Comparative Analysis of the Antioxidant Profiles Generated by the RoXsta System for Diverse Biological Fluids,’ appeared in the prestigious journal Antioxidants and was co-authored by Laureate Professor John Aitken, Memphasys’ scientific director, and a team of researchers from the University of Newcastle.
One key takeaway from the manuscript was the RoXsta system’s capability to accurately profile oxidative stress in human and animal samples.
This is an important measure since oxidative stress – which happens as a result of an imbalance between harmful reactive oxygen species (ROS) and antioxidants – is linked to infertility, cardiovascular disease, neurodegenerative disorders, cancer, and other conditions.
More specifically, RoXsta allows for close examination of antioxidant activity, assessing the ability to scavenge free radicals, suppress free radical formation, and scavenge hydrogen and organic peroxides.
Managing director and CEO of Memphasys David Ali said the manuscript was a testament to RoXsta’s transformative capabilities.
“Its diagnostic power not only reinforces Memphasys’ leadership in reproductive health but also positions us for broader market opportunities in livestock and clinical applications.
“RoXsta offers a scalable, multi-industry solution that bridges critical gaps in oxidative stress management.”
Memphasys has been trading at 0.8 cents.
Join the discussion: See what HotCopper users are saying about Memphasys Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
